Hengdian Group

Executive Summary

Hengdian Group is a diversified Chinese conglomerate with a significant pharmaceutical and healthcare division. Founded in 1975, the company operates across APIs, intermediates, CDMO services, finished drugs, medical devices, and medical services, emphasizing green chemistry principles. With a broad therapeutic focus rather than specialization in specific disease areas, Hengdian leverages its integrated capabilities to serve both domestic and international markets. The company's scale and vertical integration position it as a key player in China's pharmaceutical supply chain, though its diversification across multiple sectors (including non-pharma holdings) makes its pure-play biotech exposure limited. Hengdian's commitment to sustainable manufacturing and its established commercial stage suggest stable operations, but growth catalysts depend on regulatory approvals, CDMO contract wins, and expansion of green chemistry offerings.

Upcoming Catalysts (preview)

• Q3 2026New CDMO contract awards from global pharma clients65% success
• Q3 2026Expansion of green chemistry manufacturing capacity70% success
• Q3 2026Regulatory approval for a key finished drug product in China50% success